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Background. Campylobacter bacteremia is an uncommon condition, usually diagnosed in elderly and
immunocompromised patients.
Methods. Blood culture isolates and clinical information were collected for patients with diagnoses of
Campylobacter jejuni or Campylobacter coli bacteremia in Finland from 1998 through 2007. Bacterial species were
identiﬁed by means of polymerase chain reaction analysis, and minimal inhibitory concentrations for ciproﬂoxacin,
clindamycin, doxycycline, erythromycin, gentamicin, meropenem, and metronidazole were determined with an
agar dilution method. Medical records and mortality data within 1 year after the bacteremic episode were reviewed.
Results. The study included 76 patients (median age, 46 years), for whom bacterial isolates (C. jejuni in 73,
C. coli in 3) and clinical information were available. Most patients (70%) had no signiﬁcant underlying diseases. The
majority (82%) of the isolates were susceptible for all antimicrobial agents tested. However, antimicrobial therapy
seemed to have only a limited effect, because no differences could be detected between patients with appropriate
empirical antimicrobial treatment and those with delayed appropriate, inappropriate, or no antimicrobial therapy,
either in the duration of hospitalization (median, 4 days for both groups) or in attributable mortality. The outcome
of the infection was severe in 4 patients infected with C. jejuni; 2 died within 30 days, spondylodiscitis developed in
1, and Guillain-Barre ´ syndrome developed in 1.
Conclusions. C. jejuni and C. coli bacteremia occurred mainly in moderately young individuals without severe
underlying diseases. The bacterial isolates were predominantly susceptible to antimicrobial agents, and the outcome of
thedisease wastypicallygood,regardlessofappropriate orinappropriateantimicrobialtreatmentgiveninthehospital.
Campylobacter infection is most frequently caused by
Campylobacter jejuni or Campylobacter coli, and it is the
most common bacterial enteritis in developed countries
[1–3]. The disease is characterized by watery diarrhea,
abdominal pain, fever, and sometimes bloody stools
[1,2].Althoughtheoutcomeofdiseaseistypicallygood,
some important postinfectious complications occur.
Reactive arthritis seems to be comparatively common—a
Finnish study suggested up to 7% of individuals
infected with C. jejuni or C. coli develop reactive ar-
thritis [4]—whereas Guillain-Barre ´ syndrome is a seri-
ous although rare complication occurring after
approximately 1–3/10 000 Campylobacter infections [5,
6]. Occasionally, Campylobacter can even be cultured
from blood. The incidence of Campylobacter bacter-
emia has been shown to be ,1% of the total incidence
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C. jejuni are the 2 Campylobacter species most frequently
isolated from blood [8–11]. However, bacteremic episodes are
more typical for C. fetus infections, whereas C. jejuni and C. coli
are predominantly detected in fecal samples. Why some
C. jejuni or C. coli isolates are more invasive and enter the
bloodstream is not well understood.
Underlying conditions known to predispose for Campylo-
bacter bacteremia include HIV infection, liver diseases, and
malignancies, and the attributable mortality of Campylobacter
bacteremia has ranged between 4% and 16 % [8, 10–13]. Al-
though immunocompromised and elderly patients areespecially
prone to C. fetus bacteremia [14], some studies have shown that
C. jejuni could also be isolated from blood cultures of younger
patients without signiﬁcant underlying diseases [8, 9]. Available
data regarding antimicrobial susceptibility of blood isolates are
scarce but indicate that resistance to ﬂuoroquinolones is com-
mon, resistance to macrolides sometimes occurs, and in general
the antimicrobial susceptibility pattern of Campylobacter blood
isolates seems to reﬂect that of the fecal isolates in the country
[10, 11, 13]. However, antimicrobial susceptibility has usually
been tested with disk diffusion and not with methods giving
exact minimal inhibitory concentrations (MICs). Furthermore,
the identiﬁcation of the isolates to the species level has only
rarely been veriﬁed by molecular methods.
We have reported elsewhere some bacterial characteristics
associated with a more severe outcome of C. jejuni enteritis
[15, 16]. In the present study, we show, for the ﬁrst time, a na-
tionwide summary of the clinical characteristics and outcome of
C. jejuni and C. coli bacteremia from a 10-year period, as well as
antimicrobial susceptibility and species identiﬁcation, veriﬁed
by molecular methods, for the corresponding isolates. In
addition, to the best of our knowledge, this is the ﬁrst de-
scription of a case of Campylobacter spondylodiscitis in a patient
with concurrent C. jejuni bacteremia.
MATERIALS AND METHODS
Collection of Cases and Isolates of Campylobacter jejuni or
Campylobacter coli Bacteremia
Because of nationwide mandatory reporting, all clinical micro-
biology laboratories in Finland (population at end of study
period, 5.3million) reportallbacterialﬁndingsinbloodcultures
to the National Infectious Diseases Register, maintained by the
National Public Health Institute (later the National Institute for
Health and Welfare). Reports of all notiﬁed Campylobacter
bacteremia cases (including the Finnish personal identiﬁcation
number) in the study period, 1998 through 2007, were received
from the National Infectious Diseases Register. In addition, all
clinical microbiology laboratories in Finland with blood culture
facilities were contacted and asked to send lists of all diagnosed
Campylobacter bacteremia cases (including both reported cases
and those that should have been reported but were not) during
the study period along with the corresponding Campylobacter
blood culture isolates routinely stored at 270C. The study was
approved by the Finnish Ministry of Social Affairs and Health.
Identification of Campylobacter Isolates
The characterization of the isolates to species level was con-
ﬁrmed by polymerase chain reaction (PCR) targeting 3 separate
genes for C. jejuni and C. coli, respectively. The primer pair
C412F and C1228R (annealing temperature [AT], 58C), tar-
geting a region of the 16S ribosomal RNA gene speciﬁc for the
genus Campylobacter [17], was used to conﬁrm successful DNA
extraction and previous identiﬁcation to genus level. Multiplex
PCR was performed onall isolatespositivefor the 16S ribosomal
RNA, using the MDmapA1 upper and MDmapA2 lower pri-
mers [18] targeting the mapA gene of C. jejuni,a sw e l la st h e
COL3 upper [19] and MDCOL2 lower primers [18]t a r g e t i n g
the ceuE gene of C. coli (AT, 59C). Positive C. jejuni isolates
were further conﬁrmed by PCR using the primers HIP400F and
HIP1134R (AT, 66C) and targeting the hippuricase gene [20],
and positive C. coli isolates were conﬁrmed by PCR using the
primers CC18F and CC519R (AT, 60C) [20] and targeting the
aspartokinase gene. Cycling conditions for all PCR reactions were
as follows: 10 min at 95C, 25 cycles of 30 s at 95C, 90 s at AT
(indicated after each primer pair) and 1 min at 72C, with a ﬁnal
extension step of 10 min at 72C. The reference strains C. jejuni
NCTC11168, C. jejuni 81176, and C. coli LMG6440 were used as
positive controls. The C. coli reference strain served as negative
control for C. jejuni and the two C. jejuni strains as negative
controls for C. coli. In addition a negative control was always
present where no template DNA was added. DNA was extracted
from Campylobacter isolates harvested from blood agar plates
(Columbia agar II containing 8% vol/vol whole horse blood).
Bacteria (10
8 colony-forming units) were dissolved in 500 lLo f
ddH2O and incubated in a boiling water bath for 10 min. Cell
debris were removed by centrifugation at 18,000 g for 2 min. For
some isolates, DNA was extracted using the DNeasy Blood &
Tissue kit (Qiagen) according to the manufacturer’s instructions.
Susceptibility Testing
The MICs for ciproﬂoxacin (Bayer HealthCare), doxycycline
(Orion Pharma), erythromycin (Amdipharm), gentamicin
(Sigma-Aldrich), meropenem (Sandoz), clindamycin (Sigma-
Aldrich) and metronidazole (B. Braun Melsungen) were de-
termined by an agar dilution method according to the Clinical
and Laboratory Standards Institute (CLSI) guidelines [21].
Mueller-Hinton agar (Oxoid) plates supplemented with de-
ﬁbrinated sheep blood (5%) and incubated for 48 hours at 36C
were used. C. jejuni (American Type Culture Collection [ATCC]
33560), Helicobacter pylori (ATCC 43504) (for metronidazole),
and Staphylococcus aureus (ATCC 29213) (for clindamycin) were
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for erythromycin (MIC, #8 mg/L), ciproﬂoxacin (MIC, #1
mg/L), and doxycycline (MIC, #2 mg/L) was interpreted ac-
cording to the CLSI guidelines [22]. For clindamycin (MIC, #2
mg/L), gentamicin (MIC, #2 mg/L) and meropenem (MIC,
#4 mg/L) the susceptibility break points of the National An-
timicrobial Resistance Monitoring System (NARMS) were used
[23, 24]. For metronidazole, isolates with MICs #4 mg/L were
considered susceptible, and those with MICs $16 mg/L were
considered resistant [25].
Review of Patient Data
Medical records concerning the bacteremic episode were re-
viewed to obtain data on possible underlying diseases, medica-
tion, and travel history before the illness, as well as information
on clinical picture, laboratory parameters examined, and anti-
microbial treatment during the bacteremic episode. Amino-
glycosides, carbapenems, ﬂuoroquinolones, macrolides, and
tetracyclines were considered appropriate antimicrobial therapy
if MICs for the respective isolates indicated susceptibility.
Metronidazole and clindamycin were classiﬁed as inappropriate
therapy irrespective of MICs. Except for empirical antimicrobial
treatment, initiated on admission, all antimicrobial therapy
administered later at the hospital was regarded as delayed an-
timicrobial therapy. The Charlson index score was used to cat-
egorize comorbid diseases (weighted index of comorbidity;
range, 0–6; higher scores indicate more severe underlying dis-
eases) [26]. Mortality data were received from Statistics Finland.
Statistical Analysis
The Mann-Whitney test was used for comparison of continuous
variables. The v
2 test and Fisher’s exact test were used for
comparison of categorical variables. All tests were 2 sided, and
differences were considered statistically signiﬁcant at P , .05.
Analyses were performed with GraphPad Prism software
(version 4.03; GraphPad Software).
RESULTS
In the years 1998–2007, there were 35,393 registered Campylo-
bacter infections in Finland, and the annual incidence ranged
from 55/100 000 to 78/100 000 [27]. A total of 119 Campylo-
bacter bacteremia cases had been reported during this time
(C.jejuniin86,C.gracilisin9,C.coliin6,C.fetusin4,C.showae
in 1, and undetermined Campylobacter species in 13). The ratio
between bacteremia and all Campylobacter infections during the
study period was 0.3%. A total of 95 Campylobacter bacteremia
isolates were received and successfully cultured for further
analyses. Four strains that had originally been reported as
C.fetusand1thathadbeenreportedasC.graciliswereexcluded,
as well as 4 more strains that could not be typed with PCR as
either C. jejuni or C. coli.I na d d i t i o n ,5p a t i e n t sw e r ee x c l u d e d
because no clinical information was found, and 5 patients be-
cause of incomplete clinical information (these patients did not
receive treatment in the hospital where the blood culture was
taken). Included in the ﬁnal study were 76 patients for whom
bacterial isolates were available (C. coli in 3, C. jejuni in 73).
The seasonal variation of C. jejuni and C. coli bacteremia is
shown in Figure 1. The annual number of cases ranged from 4
(in 2002 and 2006) to 15 (in 2001), and most cases were reported
in May–August. Clinical characteristics and some laboratory
test results , grouped by the Charlson index score, are shown in
Table 1. A total of 53 patients (70%) had no signiﬁcant underlying
diseases (Charlson index score, 0); only 1 patient was known to
have HIV infection. Of the 9 patients with a Charlson index score
of 1, 5 had chronic pulmonary diseases, and 4 had either car-
diovascular disease, dementia, diabetes or mild liver disease.
Included in the group with Charlson index scores $2w e r e
5 patients with malignant diseases, 3 with moderate to severe liver
diseases, 1 with renal disease, and 5 with $2 signiﬁcant underlying
diseases. None of the severely ill patients (Charlson index
score, $2) had traveled abroad. The study included 3 children
(,18 years of age) and 3 patients .80 years of age.
The distributions of MICs for antimicrobial agents are
presented in Table 2. The majority of the isolates (82%) were
susceptible for all antimicrobials tested. All 5 patients with
ciproﬂoxacin-resistant isolates and 4 of 12 patients with met-
ronidazole-resistant isolates had traveled abroad before the
onset of symptoms. Antimicrobial treatment was administered
to 91% (69/76) of the patients during hospitalization, and ad-
ditionally to 4 patients afterward. In total, 96% of patients were
treated with antimicrobial drugs, and 39% (30/76) of the pa-
tients received appropriate empirical treatment. The variation of
hospital stay duration, C-reactive protein levels at discharge
from hospital, and mortality data according to antimicrobial
therapy are shown in Table 3.
Two patients experienced severe complications attributable to
the bacteremic episode while hospitalized, and 2 died within 30
days (Table 4). Thus, the attributable mortality was 3%. Six
more patients died within 1 year of admittance to hospital; of
these, 4 had severe underlying diseases (malignant diseases in 2,
severekidneydisease in 1,and hepatic comain 1), 1 was 95years
old, and 1 died of traumatic asphyxia. The underlying diseases,
duration of hospitalization, antimicrobial treatment, and out-
come of disease in the 4 patients with severe complications are
described in Table 4. None of the 10 excluded patients died
within 30 days after the Campylobacter-positive blood culture.
DISCUSSION
In this nationwide retrospective study, we collected C. jejuni and
C. coli bacteremia cases from a 10-year-period in Finland. For
patients in whom species could be identiﬁed and antimicrobial
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clinical characteristics were obtained from medical records. Our
results suggest that the typical patient with Campylobacter
bacteremia is a moderately young and healthy man, who re-
covers from the bacteremic episode regardless of the timing and
appropriateness of antimicrobial treatment. Furthermore, it
Figure 1. Seasonal and annual variation in Campylobacter jejuni and Campylobacter coli bacteremia cases (numbers on left axis) in Finland in 1998–
2007; data are shown for included patients (n 5 76) and patients excluded because of incomplete clinical information (n 5 5).
Table 1. Characteristics and Laboratory Results for Patients With Campylobacter jejuni or Campylobacter coli Bacteremia Grouped
According to Charlson Index Score Classification
Characteristics All patients
Charlson index score
P 01 $2
No. (%) of patients 76 53 (70) 9 (12) 14 (18) .
Male sex 56 (74) 37 (70) 8 (89) 11 (79) NS
Age, median (range), years 46 (1–95) 41 (2–88) 54 (40–95) 57 (1–83) ,.0001,
a .0017,
b .0035
c
Foreign travel before bacteremic episode
d 16 (21) 13 (25) 3 (33) 0 .03
e
Diarrhea
f 60 (79) 43 (81) 8 (89) 9 (64) NS
Fever
g 64 (84) 48 (91) 8 (89) 8 (57) .02,
a .003
c
Hospitalization, median (range), days 4 (0–94) 3.5 (0–18) 6 (1–94) 7.5 (0–45) .0006,
a .042,
b .002
c
ICU treatment 2 (3) 1 (2) 0 1 (7) NS
Appropriate empirical antimicrobial treatment
h 30 (39) 22 (42) 4 (44) 4 (29) NS
Appropriate antimicrobial treatment started in hospital
h 50 (66) 32 (60) 8 (89) 10 (71) NS
Hemoglobin, initial, g/L, median 139 144 143 113 .01,
a .0009
c
Initial leukocyte count, median, cells 3 10
9 9.1 9.3 9 7.6 NS
CRP, median, mg/L
Initial 110 131 97 69 .03
a
Peak 152 152 136 160 NS
Mortality, no. of deaths
Within 30 days 2 (3) 1 (2) 0 1 (7) NS
Within 1 year 6 (8) 1 (2) 1 (11) 4 (31) .009,
a .006
c
Data represent no. (%) of patients, unless otherwise indicated. Mann-Whitney test was used for comparison of continuous variables, and either the v
2 test or
Fisher’s exact test for comparison of categorical variables. Abbreviations: CRP, C-reactive protein; ICU, intensive care unit; NS, not signiﬁcant (P . .05).
a Comparison for Charlson index scores 0 versus $1.
b Comparison for Charlson index scores 0 versus 1.
c Comparison for Charlson index scores 0 versus $2.
d Patients known to have traveled abroad within 2 weeks before onset of symptoms.
e Comparison for Charlson index scores ,2v e r s u s$2.
f Patients known to have had diarrhea, based on hospital treatment records.
g Patients known to have had fever (.37.9C), based on hospital treatment records.
h Antimicrobial treatment with aminoglycosides, carbapenems, ﬂuoroquinolones, macrolides, and tetracyclines was considered appropriate based ont h e
susceptibility results (minimum inhibitory concentrations) of the bacterial isolates.
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land are predominantly susceptible to antimicrobial agents and
often of domestic origin.
The estimated incidence of Campylobacter bacteremia in re-
lation to enteritis ranges from 0.1% to 1% [7–9], which is in line
with the incidence of 0.3% found in the current study. In a large
study, 89% of the blood culture isolates were either C. jejuni or
C. coli [9]. Similar results were published later [8, 11], although
C. fetus was the predominant isolate in a French study [10].
Because molecular typing methods enabling exact identiﬁcation
of isolates to the species level have not usually been used, the
distribution of C. jejuni and C. coli in Campylobacter blood
culture isolates remains somewhat uncertain. One strength of
the present study is that all isolates were veriﬁed to the species
level by PCR.
Several studies have shown that Campylobacter bacteremia is
more common in older patients and in those who are immu-
nocompromised. In particular, patients with HIV infection,
malignancies, and liver diseases have been shown to be more
prone to the infection [8, 11, 13]. In the present study, patients’
underlying diseases were grouped according to the validated
Charlson index score [26]. Incontrast to ﬁndings in somerecent
Campylobacter bacteremia studies [8, 10, 11] and an older study
[13] but in line with results reported by Skirrow et al [9], we
found that the majority of patients (70%) did not have any
signiﬁcant underlying diseases and that the median age for this
particular group of patients was as low as 41 years.
Campylobacter infections in Finland show a seasonal peak
during summer months [2, 28, 29] and the majority of in-
fections are associated with foreign travel [15, 28, 29]. Although
a similar seasonal peak was also evident for Campylobacter
bacteremia, only 21% of patients were known to have traveled
abroad before the onset of illness. In addition, half of the pa-
tients had traveled only in Northern and Central Europe.
Ciproﬂoxacin resistance is extremely uncommon among
domestic Campylobacter isolates in Finland, although isolates
Table 2. MIC Distribution for 7 Antimicrobials in 76 Isolates of Campylobacter jejuni and Campylobacter coli
Antimicrobial agent
No. of isolates with given MIC (mg/L)
.002 .004 .008 .015 .03 .06 .125 .25 .5 1 2 4 8 16 32 64 128 256
Ciproﬂoxacin 0 0 0 0 0 2 34 33 2 0 0 1
a 1
a 1
a 1
a 1
a 00
Clindamycin 0 0 0 0 0 0 0 1 45 23 6 1 0 0 0 0 0 0
Doxycycline 0 0 0 0 0 0 6 52 13 2 0 0 0 1
a 2
a 00 0
Erythromycin 0 0 0 0 0 0 0 0 9 24 39 4 0 0 0 0 0 0
Gentamicin 0 0 0 0 0 0 0 1 17 58 0 0 0 0 0 0 0
Meropenem 1 39 6 23 6 1 0 0 0 0 0 0 0 0 0 0 0 0
Metronidazole 0 0 0 0 0 0 0 1 1 26 27 5 4 1
a 1
a 4
a 2
a 4
a
a Resistant isolates.
Table 3. Duration of Hospitalization, C-Reactive Protein (CRP) Level at Discharge from Hospital, and Mortality Data for Patients With
Campylobacter jejuni or Campylobacter coli Bacteremia According to Appropriateness of Antimicrobial Therapy During Hospital
Treatment Period
Antimicrobial treatment Duration of hospitalization, median, days CRP, mg/L
a Deaths within 30 days Deaths within 1 year
1. Appropriate treatment
(n 5 50)
b
5
A. Empirical (n 5 30) 4 35 1 2
B. Delayed (n 5 20) 6 22 0 3
2. Inappropriate or no treatment
(n 5 26)
3
c 26 1 1
3. Delayed, inappropriate, or
no treatment (n 5 46)
d
4
c 24 1 4
P
e .008 (1 vs 2), .03 (1A vs 1B), NS (1A vs 3) NS NS
f NS
f
a Median levels at hospital discharge, calculated for patients in whom this information was available 87%, 100%, and 77%, respectively, in groups 1A, 1B, and 2.
b Appropriateness was deﬁned according to antimicrobial susceptibility results (minimum inhibitory concentrations) of the bacterial isolates for gentamicin,
meropenem, ciproﬂoxacin, erythromycin, and doxycycline.
c The exact duration of hospitalization was not known for 1 patient in this group.
d Group 3 = Groups 1B and 2 combined.
e The Mann-Whitney test was used unless otherwise mentioned. Groups compared are indicated in parentheses; NS, not signiﬁcant (P . .05).
f Fisher’s exact test was used to compare mortality in groups 1 versus 2, 1A versus 1B, and 1A versus 3.
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has been suggested that ciproﬂoxacin-resistant Campylobacter
isolates might cause a more severe disease [31–33], but we
have shown opposite results and even reported that isolates
highly susceptible to ciproﬂoxacin (MIC, 0.06–0.25 mg/L)
seem to cause amore severe course of disease,characterized by
more frequent bloody stoolsand need forhospitalization [15].
In the current study, 91% of the C. jejuni and C. coli isolates
were highly susceptible to ciproﬂoxacin. It remains to be de-
termined whether this ﬁnding merely reﬂects the high number
of domestically obtained infections and closer travel destina-
tions or supports the hypothesis that highly susceptible iso-
lates might cause a more severe disease, such as bacteremia.
Furthermore, the present ﬁnding that the majority of bac-
teremia isolates were of domestic origin supports our recent
suggestions that Campylobacter isolates acquired in Finland
may harbor bacterial factors that lead to a more severe in-
fection [16].
C. jejuni and C. coli infections are typically self-limited, and
severe complications are quite rare. Early antimicrobial treat-
ment shortens the duration of diarrhea in enteritis patients,
although the effect is marginal [34]. Pacanowski et al reported
that failure to administer appropriate antibiotics was associated
with fatal outcome in bacteremia caused by Campylobacter
species other than C. fetus [10]. However, in a recent Spanish
report, mortality was not independently associated with in-
appropriate empirical therapy [11]. Our results support those of
the latter study, because we found no association between in-
appropriate or delayed appropriate antimicrobial treatment and
mortality. Our results could, at least in part, be due to differ-
ences in patient characteristics compared with the study by
Pacanowski et al [10], including a moderately low median age
and the lack of signiﬁcant underlying diseases in the majority of
patients.
The attributable mortality of Campylobacter bacteremia has
been estimated to be 4%–16% [8, 10–13]. Our results support
thoseofarecentDanishpopulation-basedstudy[8],because3%
of the patients in the present study died within 30 days of ad-
mittance to hospital. The deaths of other patients within 1 year
of hospital admission did not seem to be attributable to the
bacteremic episode.
Administration of appropriate antimicrobials did not seem to
affect the clinical course of disease or duration of hospitalization
to any signiﬁcant extent. Among the patients who had received
appropriate antimicrobial treatment while hospitalized, those
who had received correct empirical antimicrobial therapy
seemed to recover more rapidly. However, there was not a sig-
niﬁcant difference in the duration of hospitalization between
patients with appropriate empirical treatment and those who
had received delayed appropriate, inappropriate, or no antimi-
crobial treatment. Whether clindamycin and metronidazole
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inappropriate (irrespective of MIC results) antimicrobial treat-
ment did not affect the results on the outcome of disease to any
greater extent.
We found 2 severe complications during or immediately after
bacteremic episodes, Guillain-Barre ´ syndrome and cervical
spondylodiscitis in 1 patient each. Although C. coli has been
reported to cause spondylodiscitis [35], to the best of our
knowledge, this is the ﬁrst time a patient with C. jejuni bacter-
emia is reported to have spondylodiscitis. The bacterial aspirate,
obtained during surgical drainage of the spinal abscesses, was
negative, probably owing to the already initiated appropriate
antimicrobial treatment.
The present study is unique in that it is the ﬁrst nationwide
report presenting both clinical characteristics of patients and
antimicrobial susceptibility patterns of PCR-veriﬁed bacteremia
isolates. In Finland, the reporting of bacteremia cases is
mandatory. In our study, most of the bacterial isolates had
been stored and could be successfully cultivated for further
analyses. We also found clinical information for 88% of these
patients. This ensures that our material was representative
and not biased geographically or with regard to any patient
group.Althoughclinicalinformation was not availablefor the10
excluded patients, mortality data was available for all of them.
Only 1 of the excluded patients had died within 1 year of the
bacteremic episode; thus, the mortality rate did not differ
between included and excluded patients. The lack of clinical
information suggests that the excluded patients may not have
been treated in the hospital, and therefore their possible anti-
microbial treatment was not noted in hospital records. It is
unlikely that the exclusion of these particular patients had
a major impact on the results.
In this nationwide study from a 10-year period, C. jejuni and
C.colibacteremiawasuncommonbutshowedthesameseasonal
peak as Campylobacter enteritis in Finland. However, in contrast
to those with enteritis, patients with bacteremia had pre-
dominantly acquired their infection domestically, and bacterial
isolates only rarely showed antimicrobial resistance. Further-
more, incontrasttomanystudies fromother countries, theclear
majority of patients were moderately young and without sig-
niﬁcant underlying diseases. Mortality attributable to C. jejuni
and C. coli bacteremia was as low as 3%. The outcome of in-
fection wasingeneral good,and antimicrobialtreatment did not
seem to affect it to any greater extent. Severe complications
included single cases of Guillain-Barre ´ syndrome and spondy-
lodiscitis.
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